Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Merck & Co. Inc.
IndexDJIA S&P500 P/E39.03 EPS (ttm)1.48 Insider Own0.03% Shs Outstand2.94B Perf Week3.96%
Market Cap169.88B Forward P/E15.63 EPS next Y3.70 Insider Trans20.65% Shs Float2.94B Perf Month5.69%
Income4.40B PEG16.04 EPS next Q0.79 Inst Own74.90% Short Float0.98% Perf Quarter12.33%
Sales44.03B P/S3.86 EPS this Y-26.50% Inst Trans0.02% Short Ratio2.30 Perf Half Y26.05%
Book/sh17.00 P/B3.40 EPS next Y7.51% ROA5.60% Target Price57.44 Perf Year24.83%
Cash/sh5.95 P/C9.72 EPS next 5Y2.43% ROE12.10% 52W Range43.07 - 58.32 Perf YTD16.33%
Dividend1.76 P/FCF34.33 EPS past 5Y-16.50% ROI6.60% 52W High-1.49% Beta0.48
Dividend %3.05% Quick Ratio1.60 Sales past 5Y13.00% Gross Margin61.50% 52W Low33.40% ATR1.16
Employees77300 Current Ratio2.00 Sales Q/Q-3.60% Oper. Margin17.40% RSI (14)59.22 Volatility1.83% 2.08%
OptionableYes Debt/Eq0.50 EPS Q/Q-13.30% Profit Margin13.60% Rel Volume0.51 Prev Close57.77
ShortableYes LT Debt/Eq0.41 EarningsApr 29 BMO Payout84.70% Avg Volume12.48M Price57.45
Recom2.30 SMA202.29% SMA502.79% SMA20015.33% Volume5,549,164 Change-0.55%
11-Apr-14Reiterated MKM Partners Buy $64 → $70
05-Feb-14Reiterated Argus Buy $54 → $62
14-Jan-14Reiterated MKM Partners Buy $59 → $64
03-Jun-13Reiterated MKM Partners Buy $54 → $59
15-Apr-13Reiterated Barclays Overweight $45 → $60
04-Feb-13Reiterated MKM Partners Buy $51 → $52
04-Feb-13Reiterated Barclays Overweight $46 → $45
20-Nov-12Upgrade MKM Partners Neutral → Buy $47 → $51
17-Oct-12Reiterated MP Advisors Outperform $45 → $50
30-Jul-12Reiterated UBS Buy $45 → $50
13-Jul-12Upgrade MP Advisors Market Perform → Outperform $45
03-Feb-12Reiterated Barclays Capital Overweight $38 → $40
03-Feb-12Downgrade MKM Partners Buy → Neutral $42 → $40
29-Nov-11Initiated MKM Partners Buy $38
14-Sep-11Reiterated Barclays Capital Overweight $41 → $38
16-May-11Reiterated UBS Buy $40 → $42
04-Feb-11Reiterated UBS Buy $42 → $40
24-Jan-11Reiterated Deutsche Bank Buy $48 → $43
24-Jan-11Reiterated Barclays Capital Overweight $43 → $41
21-Jan-11Reiterated Deutsche Bank Buy $48 → $43
23-Apr-14 11:39AM  Gilead, Illumina Q1 Earnings Win Wall Street's Love at Investor's Business Daily
10:04AM  Say Hello to the New Fastest Growing Drug in History! at Motley Fool
08:00AM  Merck and Award-Winning Actress S. Epatha Merkerson Challenge Americans with Type 2 Diabetes to Get to Their Goals PR Newswire
12:08AM  Asia shares mixed on lackluster China data AP
22-Apr-14 11:49AM  Novartis, Glaxo Swap Units; Lilly Buying Animal Biz at Investor's Business Daily
10:48AM  [video] Allergan, Valeant perfect match: CEO at CNBC
09:32AM  Why Johnson & Johnson Is Outperforming the Dow at Motley Fool
09:09AM  [video] Novartis strikes multiple deals at CNBC
08:45AM  Valeant, Ackman make $45.6B Allergan bid AP
12:03AM  Botox maker Allergan draws bid from Valeant AP
21-Apr-14 05:41PM  Value stocks to stay in vogue, as momentum fades at CNBC
05:05PM  Value stocks to stay in vogue, as momentum fades at CNBC
03:34PM  Value stocks to stay in vogue, as momentum fades at CNBC
12:44PM  Nothing Generic About Mylan at Forbes
12:08PM  Interesting May Stock Options For MRK at TheStreet
11:13AM  Pfizer, AstraZeneca Rise On Report Of Merger Talks at Investor's Business Daily
10:50AM  [video] Pfizer considers AstraZeneca bid: Report at CNBC
20-Apr-14 06:33AM  Dow Dogs Are Front Of The Pack at Seeking Alpha
18-Apr-14 01:51PM  Jim Cramer: We're in the Grips of a Struggle at TheStreet
09:30AM  Will Merck & Co. Inc Unseat Biotech's Hottest Drug? at Motley Fool
17-Apr-14 06:22PM  FDA Approves Mercks RAGWITEK (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults Business Wire
05:11PM  FDA OKs Merck tablet to reduce ragweed allergies AP
03:57PM  FDA OKs Merck tablet to reduce ragweed allergies AP
03:48PM  P&G, AT&T Among Citi's 'Bond Refugee' Yieldy Dividend Stocks at Barrons.com
02:28PM  UnitedHealth: New hepatitis C drug costs far more than forecast Reuters
11:42AM  Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides at Motley Fool
11:34AM  [$$] Big Pharma Q1 Sales Hurt by Exchange Rates at Barrons.com
07:38AM  Ready For A Rebound? Gilead's $1000 Pill at Seeking Alpha
05:21AM  2 Reasons Why Merck & Co. Is Crushing the Dow at Motley Fool
16-Apr-14 05:38PM  Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer? at Motley Fool
04:22PM  Is Merck a Hot Stock? at Wall St. Cheat Sheet
03:23PM  As big pharma backs away, Alnylam sees deja vu at CNBC
02:28PM  Will Recent News Hurt GlaxoSmithKline? at Wall St. Cheat Sheet
01:38PM  Dear Jenny McCarthy, Here's How Many Lives Could Be Saved Cheaply By Making Vaccines More Widely Available at Forbes
01:14PM  Jobs outlook for Class of 2014 looks like this... at CNBC
12:48PM  Smartphone apps remind patients to take their meds AP
08:04AM  Goodbye Injections and Sneezes: FDA Approves Mercks Allergy Tablet at Wall St. Cheat Sheet
05:30AM  Reckitt leans towards pharmaceuticals spin-off Reuters
15-Apr-14 06:32PM  How Much Has Merck Shaken Up the Hepatitis C Race? at Motley Fool
04:15PM  FDA Nod for Merck's Grastek Zacks
03:15PM  FDA OKs Merck tablet to reduce grass allergies AP
02:56PM  This Forgotten Pharma Could Be a Hit for Your Portfolio at Motley Fool
02:07PM  A Wall Street Transcript Interview with Kenneth M. Conrad, Ph.D., CFA, a Portfolio Manager at BMO Global Asset Management for the BMO Custom Quantitative Solutions Group: Finding Attractive Yields in Financials, IT and Health Care Wall Street Transcript
09:40AM  Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo? at Motley Fool
09:04AM  Big Pharma's Turn On RNAi Shows That New Technologies Don't Guarantee R&D Success at Forbes
08:30AM  Johnson & Johnson Earnings Point to New 52-Week High 24/7 Wall St.
14-Apr-14 06:14PM  Amgen's Conundrum at Motley Fool
05:59PM  FDA Approves Mercks GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults Business Wire
04:30PM  Dow Today: International Business Machines (IBM) Leads The Day Higher, Merck (MRK) Lags at TheStreet
04:10PM  Hard-to-Cure Patients May Benefit from Merck's HCV Drug Zacks
12:10PM  One Put, One Call Option To Know About For Merck & Co. at TheStreet
08:07AM  Can Merck, Bristol-Myers, or AbbVie Compete with Gileads Cure for Hepatitis C? at Wall St. Cheat Sheet
05:57AM  Price of New Hepatitis C Drugs Not So Daunting After All at Bloomberg
13-Apr-14 10:00AM  Got Allergies? FDA to the Rescue at Motley Fool
12-Apr-14 01:02AM  Merck Shouts "Me, Too!" But Will It Matter? at Motley Fool
11-Apr-14 04:01PM  The 4 Stocks That Sank the Market at 24/7 Wall St.
02:18PM  Is Gilead Sciences a Value Stock? at Barrons.com
09:22AM  [video] Cramer's Mad Dash: GILD not alone at CNBC
01:00AM  Mercks Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection Business Wire
10-Apr-14 06:07PM  As Hep C Cure Rate Hits 98%, Merck Challenges Gilead Investor's Business Daily
04:22PM  Roche's Competitive Advantage at Seeking Alpha
03:46PM  [$$] Merck's Hepatitis C Drug May Boost Stock at Barrons.com
03:30PM  Merck Up on Encouraging HCV Data Zacks
12:45PM  Midday movers: Netflix, Tesla Motors, CBS & More at CNBC
11:48AM  Merck Hepatitis C Combo Scores 98% Cure Rate Investor's Business Daily
11:48AM  Merck Hepatitis C Combo Scores 98% Cure Rate at Investor's Business Daily
11:43AM  [video] Pfizer CEO worries about ACA coverage at CNBC
10:57AM  May 30th Options Now Available For Merck (MRK) at TheStreet
10:36AM  Gilead Sciences: How Big a Threat is Merck? at Barrons.com
09:13AM  [$$] Merck's Hepatitis C Drug Shows 98% Cure Rate at The Wall Street Journal
08:46AM  Today's Biotech Stocks to Watch: Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Inc. at Motley Fool
08:44AM  Why Merck (MRK) Stock Is Higher This Morning at TheStreet
08:38AM  [$$] Merck's Hepatitis C Drug Shows 98% Cure Rate at The Wall Street Journal
01:00AM  Merck hepatitis C drugs shine in easier to treat patients -study Reuters
01:00AM  Merck Data Show Potent Rival to Gileads Hepatitis C Pill at Bloomberg
01:00AM  Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection Business Wire
09-Apr-14 04:38PM  Why the Dow Jones Jumped 180 Points Today at Motley Fool
04:36PM  Ignore Momentum Advice -- Buy Real Growth Stocks at Forbes
02:20PM  [video] Is There a Biotech Bubble? at Bloomberg
12:13PM  Merck Moves the Dow and Facebook Pops as Earnings Season Gets Started at Motley Fool
11:43AM  Gilead defended by analysts after recent pullback at theflyonthewall.com
11:04AM  "Change the law or stop complaining about it." Hot Stock Minute
09:56AM  US stocks rise on Alcoa earnings; La Quinta falls in market debut at CNBC
08-Apr-14 07:19PM  Untaxed U.S. corporate profits held overseas top $2.1 trillion: study Reuters
07:06PM  Untaxed U.S. corporate profits held overseas top $2.1 trln -study Reuters
06:31PM  Merck Launches Hail Mary Lung Cancer Trial at Motley Fool
05:55PM  Merck KGaA Starts Study on Tecemotide Zacks
12:55PM  Takeda: a fine mess at Financial Times
11:23AM  Healthcare Investors Suffering Losses While Drug-Pricing War Rages at TheStreet
08:32AM  Fort Hood shootings could stymie veteran hiring at CNBC
07-Apr-14 05:41PM  India to Missouri Deals Drive Busy $47 Billion Day of Takeovers at Bloomberg
02:02PM  Here's How Intel Corp.'s Executive Bonus Tweaks Help Shareholders Like You and Me at Motley Fool
06-Apr-14 10:30AM  Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Mercks Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014 Business Wire
05-Apr-14 01:14AM  Is Merck A Good Dividend Pick? at Seeking Alpha
04-Apr-14 04:00PM  Merck KGaA and Auxogyn Collaborate Zacks
09:31AM  3 Under-Loved Dividend Darlings for Your Portfolio at Motley Fool
08:07AM  Merck, Ferring announce collaboration with WHO at theflyonthewall.com
08:00AM  Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth Business Wire
03-Apr-14 04:10PM  Merck KGaA, Pfizer and Broad Institute Collaborate Zacks
12:03PM  The markets rigged, you say? When wasnt it? at MarketWatch
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company's Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company's Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., and Sanofi Pasteur S.A. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOApr 10Option Exercise34.2012,876440,307320,541Apr 11 09:53 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Sale57.2410,047575,108310,494Apr 11 09:53 AM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Option Exercise39.90145,2255,794,929267,070Apr 04 05:07 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Sale56.43145,2258,195,164121,845Apr 04 05:07 PM
Golestani ClarkEVP & Chief Info OfficerFeb 14Option Exercise48.246,375307,53012,036Feb 14 05:11 PM
Golestani ClarkEVP & Chief Info OfficerFeb 14Sale55.475,990332,2766,046Feb 14 05:11 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareFeb 13Option Exercise36.5649,7501,818,86071,457Feb 14 11:17 AM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareFeb 13Sale55.0443,8702,414,57027,587Feb 14 11:17 AM
Schechter Adam HEVP & Pres-Global Human HealthFeb 11Option Exercise47.6518,000857,70518,000Feb 13 10:12 AM
Canan JohnSr.V-P Finc-Global ControllerFeb 11Option Exercise48.2410,000482,40020,697Feb 11 05:07 PM
FRAZIER KENNETH CChairman, President & CEOFeb 11Option Exercise48.2445,0002,170,800304,349Feb 11 05:34 PM
FRAZIER KENNETH CChairman, President & CEOFeb 11Sale54.5241,5202,263,683262,829Feb 11 05:34 PM
Canan JohnSr.V-P Finc-Global ControllerFeb 11Sale55.7010,000557,00210,697Feb 11 05:07 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 11Sale55.6118,0001,000,9350Feb 13 10:12 AM
WEEKS WENDELL PDirectorFeb 10Option Exercise47.235,000236,1505,100Feb 11 03:41 PM
WENDELL PETER CDirectorFeb 10Option Exercise47.235,000236,1506,000Feb 11 03:48 PM
Deese Willie AExe V-P & Pres. MMDFeb 10Option Exercise48.2420,000964,800156,049Feb 11 03:54 PM
Deese Willie AExe V-P & Pres. MMDFeb 10Sale54.6850,0002,734,155106,049Feb 11 03:54 PM
WENDELL PETER CDirectorFeb 10Sale54.445,000272,1931,000Feb 11 03:48 PM
WEEKS WENDELL PDirectorFeb 10Sale54.265,000271,283100Feb 11 03:41 PM
Deese Willie AExe V-P & Pres. MMDJan 27Option Exercise47.7930,0001,433,700136,049Jan 28 10:09 AM